| Literature DB >> 28276486 |
Wenjuan Sun1, Ting He1, Chunfu Qin1, Kai Qiu1, Xin Zhang1, Yanhong Luo1, Defa Li1, Jingdong Yin1.
Abstract
Mechanism controlling myo-adipogenic balance in skeletal muscle is of great significance for human skeletal muscle dysfunction and myopathies as well as livestock meat quality. In the present study, two cell subpopulations with particular potency of adipogenic or myogenic differentiation were isolated from neonatal porcine longissimus dorsi using the preplate method to detect mechanisms underlying distinct fate commitment of myogenic and adipogenic cells in skeletal muscle. Both cells share a common surface expression profile of CD29+CD31-CD34-CD90+CD105+, verifying their mesenchymal origin. A total of 448 differentially expressed genes (DEGs) (FDR < 0.05 and |log2 FC| ≥ 1) between two distinct cells were identified via RNA-seq, including 358 up-regulated and 90 down-regulated genes in myogenic cells compared with adipogenic cells. The results of functional annotation and enrichment showed that 42 DEGs were implicated in cell differentiation, among them PDGFRα, ITGA3, ITGB6, MLCK and MLC acted as hubs between environment information processing and cellular process, indicating that the interaction of the two categories exerts an important role in distinct fate commitment of myogenic and adipogenic cells. Particularly, we are first to show that up-regulation of intracellular Ca2+-MLCK and Rho-DMPK, and subsequently elevated MLC, may contribute to the distinct commitment of myogenic and adipogenic lineages via mediating cytoskeleton dynamics.Entities:
Mesh:
Year: 2017 PMID: 28276486 PMCID: PMC5343460 DOI: 10.1038/srep44133
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Isolation and identification of adipogenic (Adi) and myogenic (Myo) cells from porcine skeletal muscle by preplate technique.
(a) Procedure of isolating adipogenic (Adi) and myogenic (Myo) cells. (b) Morphology of adipogenic (Adi) and myogenic (Myo) cells at passage 3, the magnification of microscope is (4 * 10). (c) porcine skeletal muscle-derived adipogenic (Adi) and myogenic (Myo) cells were grown on collagen-I coated dishes in in myogenesis induction medium for 5 days, cell were fixed, stained with Gimsa, the magnification of microscope is (10 * 10) (d) or in adipogenesis induction medium for 10 days, cell were fixed, stained with oil-red O, the magnification of microscope is (10 * 10). (e) Quantitative analysis of lipid droplet by oil-red O OD. Measurement of adipogenic (Adi) and myogenic (Myo) cells that after adipogenesis induction at d10. Values are means (n = 3) ± SEM, *represent significant difference between adipogenic (Adi) and myogenic (Myo) cells with p < 0.05. (f) Gene expression (n = 3) analysis of MyoD and PPARG in pre-induction adipogenic and myogenic cells by RNA-sequencing. (g) and (h) RT-qPCR analysis of adipogenesis- and myogenesis-related gene expression after adipogenic or myogenic induction. The data of each type cells comes from three replicates. (i) RT-qPCR analysis gene expression of myogenic markers (PAX7 and Desmin) and adipogenic marker (PDGFRα) and in pre-induction adipogenic (Adi) and myogenic (Myo) cells. The data of each type cells comes from three replicates. The procedure of isolating adipogenic (Adi) and myogenic (Myo) cells draw by Adobe Photoshop (CS5).
Figure 2Expression of mesenchymal surface marker in porcine skeletal muscle-derived adipogenic and myogenic cells.
(a) Representative flow cytometry analyses of adipogenic adipogenic (Adi) and myogenic (Myo) cells. (b) Percentages of positive cells for CD29 (APC), CD90 (PE-Cy7), and CD34 phycoerythrin (PE) were determined by flow cytometry. (c) Gene expression level (n = 3) of CD29, CD90, CD105, CD34, and CD31 analyzed by RNA-seq. The data of each type cells comes from three replicates. FlowJo (Tree Star) was used for all flow cytometry analysis.
Figure 3DEGs between adipogenic and myogenic cells based on the RNA-sequencing data.
(a) Genes were categorized into DEGs (plots that off the two red line) based on their position to the diagonal (FPKM1 represent adipogenic (Adi) cells, FPKM2 represent myogenic (Myo)). (b) Overview of DEGs numbers between adipogenic (Adi) and myogenic (Myo) cells. (c) Hierarchical clustering of top 40 DEGs (top 20 genes with either higher or lower expression in myogenic compared to adipogenic cells) between adipogenic (Adi) and myogenic (Myo) cells. The data of each type cells comes from three replicates. Heat-maps were generated by MeV (4.9.0).
Figure 4RNA-seq examination via hierachization clustering and validation via RT-qPCR.
(a) All DEGs between adipogenic (Adi) and myogenic (Myo) cells based hierachization clustering. (b) Fold change (FC) of 9 selected DEGs calculated with mRNA expressions of myogenic vs adipogenic cells determined via RNA-seq (n = 3) and RT-qPCR (n = 3). (c) The correlation of fold changes in gene expression between the RNA-seq and RT-qPCR (Pearson correlation analysis were conducted by SAS 9.1). Heat-maps were generated by MeV (4.9.0).
List of significantly enriched cell differentiation-related GO terms (q < 0.05) identified in DEGs between adipogenic and myogenic cells.
| Genes | U | D | Go terms | q value |
|---|---|---|---|---|
| Genes relating to cell differentiation and fate determination | ||||
| FGD4, LRFN2, JAG2, CEBPA, COL8A2, COL2A1, FSCB, TRIM55, ILDR1, NFATC2, PDGFA, SLIT2, TMPRSS11F, ARHGAP24, AGTR1, MLCK, COL8A1, MEGF10, MEOX2, PPFIA4, GPR39, ITGB6, STK17B, ECEL1, HES6, SLIT3, SCN4A, DPYSL2, RRAD, TNXB, NOTCH3, SRPK3, IGF2, FSCN2, CYR61, PKNOX2, TBX2, TRIM63, SEMA6B, OBSL1, LZTS2, LZTS1 | 36 | 6 | cell differentiation (GO: 0030154); | 0.031 |
| JAG2, FZD6, HEY1, SIX2, PITX2, FZD4, HES6, HEYL | 7 | 1 | negative regulation of cell differentiation (GO: 0045596); | 0.037 |
| MYF5, SOX11, KLF14, ANKRD1, MYOG, HEYL, MEF2C, MET, WNT5B, CEBPA, PITX2, MAMSTR, SIX1, MYLPF, SMYD1 | 14 | 1 | skeletal muscle cell differentiation (GO: 0035914); | 0.005 |
| myotube differentiation (GO: 0014902); | 0.013 | |||
| positive regulation of myotube differentiation (GO: 0010831); | 0.037 | |||
| muscle cell fate specification (GO: 0042694); | 0.029 | |||
| muscle cell fate determination (GO: 0007521); | 0.021 | |||
| ureter smooth muscle cell differentiation (GO: 0072193); | 0.041 | |||
| SIX2, MYL2, MEF2C, TBX2, MEDAG, PITX3, PPARG, ARL4A | 3 | 0 | positive regulation of fat cell differentiation (GO: 0045600); | 0.048 |
| brown fat cell differentiation (GO: 0050873); | 0.050 | |||
| NOTCH3, COL1A1, TRIM54, RHOB, SOX11, MEF2C, HEYL, NBL1, DMD, SIX1, HEY1, SIX2, HES6, TIMP2 | 15 | 0 | positive regulation of neuron differentiation (GO: 0045666); | 0.029 |
| regulation of neuron differentiation (GO: 0045664); | 0.013 | |||
| neuron fate commitment (GO: 0048663); | 0.050 | |||
| Cell components of extracellular matrix, focal adhension, cytoskeleton | ||||
| SHROOM3, SGCG, KLHL40, RAPSN, CNN1, ABLIM3, STK17B, SGCA, KSR1, MICAL2, CSRP1, SRPK3, DMD, LOC102159034, DMPK, CAP2, MYZAP, RASA1, CORO2A, MUSK, PDGFA, FSCN1, FZD4, XIRP2, MET, FSCN2, TUBB2B, TPM1, ACTC1, ANK3, ACTA2, TUBA4A, TUBA1D, DES, TUBB6, ITGA2B, ITGB6, ITGA9, RND2, PDLIM3, SAMD14, STK26, MYO18A, MYH11, TPPP3, FGF13, FGF11, MLCK, PTPRK, SLC9A3R, TRIM54, LOC100626707, ACTN2, DPYSL2 | 50 | 5 | cytoskeleton (GO: 0005856); | 0.017 |
| actin cytoskeleton organization (GO: 0030036); | 0.021 | |||
| integrin-mediated signaling pathway (GO: 0007229); | 0.036 | |||
| actin filament bundle assembly (GO: 0051017); | 0.029 | |||
| actin filament organization (GO: 0007015); | 0.045 | |||
| microtubule polymerization (GO: 0046785); | 0.021 | |||
| skeletal muscle thin filament assembly (GO: 0030240); | 0.029 | |||
| actin filament depolymerization (GO: 0030042); | 0.037 | |||
| actomyosin structure organization (GO: 0031032); | 0.037 | |||
| actin-myosin filament sliding (GO: 0033275); | 0.041 | |||
| SCUBE1, JAG2, MMP15, LOC100155429, OLFML2B, BCAR3, FLRT3, FGFR2, TENM1, MEGF10, SCUBE2, FZD4, ADAMTS8, TENM3, ITGB6, SNED1, FAM83G, NOTCH3, COL1A1, FN1, TNC, SOD3 | 14 | 8 | extracellular matrix (GO: 0031012); | 0.003 |
| PTPRK, LOC100620787, ACTN2 | 2 | 1 | focal adhesion assembly (GO: 0048041); | 0.045 |
| Binding and cell adhension | ||||
| LRFN2, JAG2, LOC100155429, RASA1, COL2A1, COL15A1, FSCB, BCAR3, FLRT3, RHOB, FLT1, EFNB2, MEGF10, TGFBI, MCAM, NRCAM, C1QTNF3, AATK, NOTCH3, CYR61, LSAMP, COL11A2, LOC100620394, MUSK, ABLIM3, IL18, RND2, CYTIP, DMPK, PXM1, ITGA2B, NTM, PECAM1, ITGA9, TNXB, FN1, TNC, LOC100626707, LAMA2 | 30 | 10 | cell adhesion (GO: 0007155) | 5.48E-05 |
| regulation of cell adhesion (GO: 0030155) | 0.046 | |||
| MUSK, RHOB, ITGB6, EPDR1, TRIM54, COL8A2, FZD6, ABLIM3, RND2, SNED1, CDK3, TNXB, TNC, PPARG, PDGFRα | 9 | 6 | cell-matrix adhesion (GO: 0007160) | 0.006 |
| cell-substrate adhesion (GO: 0031589) | 0.014 | |||
| CAP2, TPM1, NCALD, SHROOM3, MYOZ2, ANKRD1, XIRP1, MLCK, CNN1, ABLIM3, TAGLN, CXCR4, XIRP2, FLNC, MET, WIPF3, MYO1D, MICAL2, CSRP1, TNNT1, DMD, MYH11, NEXN, CORO2A, FSCN1, ACTN2, FSCN2, PKNOX2, ACTC1 | 29 | 0 | actin binding (GO: 0003779) | 1.25E-05 |
| actin filament binding (GO: 0051015) | 0.008 | |||
| actin monomer binding (GO: 0003785) | 0.028 | |||
| myosin binding (GO: 0017022) | 0.034 | |||
| tropomyosin binding (GO: 0005523) | 0.037 | |||
| integrin binding (GO: 0005178) | 0.031 | |||
| CELSR1, SAMD1, JAG2, CDH15, MMP15, RYR1, NCALD, TPD52, NINL, MYLPF, SLIT2, PCDH7, PCDH17, MYL2, PLA2G3, ACTN2, SCUBE2, CDH6, SLIT3, SGCA, EPDR1, NOTCH3, MLCK, CDH2, COL1A1, DMD, SCUBE1, C1R, SNED1, ATP2A3, RHBDL3 | 26 | 5 | calcium ion binding (GO: 0005509) | 0.008 |
| RYR1, HRC, ACTN2, HOMER1, FGF13, FGF11 | 6 | 0 | ion channel binding (GO: 0044325) | 0.041 |
| JAG2, LOC100155429, NOTCH3, LOC106506957, MAMDC2 | 5 | 0 | glycosaminoglycan binding (GO: 0005539) | 0.004 |
| PDGFA, PDGFD, PDGFC, PDGFRα | 3 | 1 | platelet-derived growth factor receptor binding (GO: 0005161) | 0.003 |
| ALDH1A1, THRB | 1 | 1 | thyroid hormone binding (GO: 0070324) | 0.003 |
| Signaling pathways | ||||
| MYO1D, ADORA1, STK26, IL1RAP, FGF13 | 5 | 0 | calcium-mediated signaling (GO: 0019722); | 0.006 |
| TNXB, NOTCH3, HEYL | 2 | 1 | Notch signaling pathway (GO: 0007219); | 0.041 |
| COL1A1, LRRC15 | 2 | 0 | Wnt signaling pathway, calcium modulating pathway (GO: 0007223); | 0.029 |
| LRRC15, SBK1 | positive regulation of Wnt signaling pathway, planar cell polarity pathway (GO: 2000096) | 0.041 | ||
| FGF11, COL1A1, PTGIR, PDGFRα | 3 | 1 | regulation of chemotaxis (GO: 0050920); | 0.013 |
| negative regulation of chemokine-mediated signaling pathway (GO: 0070100); | 0.041 | |||
| WNT5B, EDN1, LRFN2, JAG2, RYR1, RASA1, FSCB, NCALD, SLIT2, EFNB2, ADAMTS14, RIPK4, GPC3, MEGF10, ABLIM3, SYTL2, SCUBE1, GPR68, ZNF423, AGTR1 | 16 | 4 | cell surface receptor signaling pathway (GO: 0007166); | 0.041 |
| DMPK | 1 | 0 | negative regulation of platelet-derived growth factor receptor signaling(GO: 0010642) | 0.041 |
| Proteins modification | ||||
| MUSK, FLT1, LEPR, PDGFA, PDGFD, PDGFC, DDR1AATK, FGFR2, CNTFR, KSR1, PDGFRα | 8 | 4 | peptidyl-tyrosine phosphorylation (GO: 0018108); | 0.021 |
| regulation of JUN kinase activity (GO: 0043506); | 0.029 | |||
| peptidyl-tyrosin autophosphorylation (GO: 0038083); | 0.029 | |||
| regulation of peptidyl-tyrosine phosphorylation (GO: 0050730); | 0.032 | |||
| TUBB2B, TUBA4A, TUBA1D, TUBB6 | 4 | 0 | protein polymerization (GO: 0051258); | 0.042 |
| FSCB, MEGF10, SYTL2, HES6, C1QTNF3, AATK, ADORA1, IL1RAP, FGF13, FGF11, LRRC15, DMPK1, GPR68, TNXB | 12 | 2 | positive regulation of signal transduction (GO: 0009967); | 0.026 |
U: number of up-regulated genes in myogenic cells, D: number of down-regulated genes in myogenic cells.
Figure 5KEGG analysis of DEGs and their relationship with cell differentiation.
(a) Significantly enrichment pathways (q < 0.05) based on identified DEGs. (The number in the right of columns represented the number of DEGs that involved in those enrichment pathway). (b) Transcriptional regulatory network of DEGs in key KEGG pathways, which included by environmental information processing and cellular process. Diamonds represent KEGG pathways, rectangles represent genes involved in the KEGG pathways and the triangle represent DEGs related to cell differentiation. The colour of the nodes represents gene expression status (red means genes up-regulated in Myo, green means down-regulated in Myo). Networks were visualized by Cytoscape (v3.2.1).
Figure 6Intracellular calcium concentration differed in adipogenic and myogenic cells of porcine.
(a) Average Ca2+ signals of adipogenic (Adi) and myogenic cells (Myo) compared with unlabled control (the blue represented unlabled control, the green represented fluro-3 labled cell). (b) Average Ca2+ signals of adipogenic (Adi) and myogenic cells (Myo) from porcine skeletal muscle, the data of every group comes from three replicates. (c) Mean fluro-3 intensity of adipogenic (Adi) and myogenic cells (Myo) from porcine skeletal muscle, *significant difference between adipogenic (Adi) and myogenic cells (Myo) with p < 0.05.
Figure 7The potential regulatory network of fate determination of myogenic and adipogenic cells derived from porcine skeletal muscle.
The colour of the nodes represent gene expression status (red means up-regulated in myogenic cells (Myo), green means down-regulated in Myo, blue means genes including both up- or down-regulated genes in Myo, IP3R was up-regulated in myogenic cells with FC = 1.36, FDR < 0.05). This model was visualized by Adobe Illustrator (CS5).